Cresset Asset Management, LLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Cresset Asset Management, LLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$2,486,307
-14.7%
36,525
+2.3%
0.01%
+150.0%
Q2 2023$2,915,379
+115.1%
35,715
+95.5%
0.00%
-85.2%
Q1 2023$1,355,229
-6.2%
18,267
+259.0%
0.03%
+50.0%
Q3 2022$1,445,000
-14.9%
5,089
+3.5%
0.02%
-14.3%
Q2 2022$1,698,000
+613.4%
4,915
+973.1%
0.02%
+950.0%
Q4 2021$238,000
-72.6%
458
-74.4%
0.00%
-83.3%
Q3 2021$868,000
+124.9%
1,792
+109.6%
0.01%
+140.0%
Q2 2021$386,000
+24.9%
855
+5.9%
0.01%0.0%
Q1 2021$309,000
+34.3%
807
+11.6%
0.01%
+25.0%
Q4 2020$230,0007230.00%
Other shareholders
BIO-TECHNE CORP shareholders Q4 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders